Related Experiment Video
Updated: Sep 28, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Impairing memory reconsolidation with propranolol in healthy and clinical samples: a meta-analysis
Sereena Pigeon1, Michelle Lonergan1, Olivia Rotondo1
1From McGill University, Montréal, Que., Canada (Pigeon, Lonergan, Rotondo, Brunet); the Douglas Mental Health University Institute Research Center, Montréal, Que., Canada (Pigeon, Lonergan, Rotondo, Brunet); the School of Psychology, University of Ottawa, Ottawa, Ont., Canada (Lonergan); and the Department of Psychiatry, Harvard Medical School, Charlestown, Mass., USA (Pitman).
Background:
Reconsolidation impairment using propranolol is a novel intervention for mental disorders with an emotional memory at their core. In this systematic review and meta-analysis, we examined the evidence for this intervention in healthy and clinical adult samples.
Methods:
We searched 8 databases for randomized, double-blind studies that involved at least 1 propranolol group and 1 placebo group. We conducted a meta-analysis of 14 studies (n = 478) in healthy adults and 12 studies in clinical samples (n = 446).
Results:
Compared to placebo, reconsolidation impairment under propranolol resulted in reduced recall of aversive material and cue-elicited conditioned emotional responses in healthy adults, as evidenced by an effect size (Hedges g) of -0.51 (p = 0.002, 2-tailed). Moreover, compared to placebo, reconsolidation impairment under propranolol alleviated psychiatric symptoms and reduced cue-elicited reactivity in clinical samples with posttraumatic stress disorder, addiction or phobia (g = -0.42, p = 0.010).
Limitations:
Methodological differences between studies posed an obstacle for identifying sources of heterogeneity.
Conclusion:
Reconsolidation impairment is a robust, well-replicated phenomenon in humans. Its clinical use is promising and deserves further controlled investigation.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

